Related Experiment Video
Updated: Apr 28, 2026
09:57
Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles
Published on: June 28, 2021
1.7K
Curcumin blocks interleukin-1 signaling in chondrosarcoma cells
Thomas Kalinski1, Saadettin Sel2, Heiko Hütten3
1Department of Pathology, Otto-von-Guericke-University, Magdeburg, Germany.
Plos One
|June 6, 2014
Summary
Curcumin inhibits Interleukin-1 (IL-1) signaling and VEGF-A expression in chondrosarcoma cells. This suggests IL-1 blockade, using agents like curcumin, could be a novel treatment for chondrosarcoma.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- Interleukin-1 (IL-1) signaling is implicated in both inflammatory and malignant processes.
- IL-1 signaling activates nuclear factor kappa B (NF-κB), promoting genes involved in cancer progression like VEGF-A.
- Microenvironment-derived IL-1β is crucial for tumor invasion and angiogenesis, particularly in chondrosarcomas.
Purpose of the Study:
- To investigate IL-1β-induced signal transduction and VEGF-A expression in chondrosarcoma cells.
- To evaluate the effects of Curcumin on IL-1 signaling, VEGF-A expression, and angiogenesis in chondrosarcoma.
- To analyze NF-κB-related gene expression in response to IL-1β and Curcumin.
Main Methods:
- Utilized C3842 and SW1353 chondrosarcoma cell lines.
- Performed in vitro angiogenesis assays.
- Analyzed IL-1β-induced signal transduction, VEGF-A expression, and NF-κB-related gene expression.
- Investigated the inhibitory effect of Curcumin on IL-1 receptor-associated kinase (IRAK) recruitment.
Main Results:
- Curcumin effectively blocked IL-1 signaling and VEGF-A expression in chondrosarcoma cells.
- Curcumin inhibited IL-1β-induced angiogenesis in vitro.
- Curcumin suppressed IL-1β-induced NF-κB-related gene expression.
Conclusions:
- IL-1 signaling blockade is a potential therapeutic strategy for chondrosarcoma.
- Curcumin and its derivatives show promise in inhibiting chondrosarcoma progression by blocking IL-1 signaling.
- Targeting IL-1 pathways represents a novel avenue for chondrosarcoma treatment.
Related Concept Videos
02:26NF-κB-dependent Signaling Pathway
7.5K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.5K
01:20The JAK-STAT Signaling Pathway
10.1K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
10.1K
02:34Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K